secwatch.observer — SEC 8-K summary
======================================

Issuer:     Korro Bio, Inc. (KRRO)
CIK:        0001703647
Form:       8-K
Filed at:   2026-03-09T23:59:59+00:00
Accession:  0001193125-26-097575
Event type: other_material
Sentiment:  positive
Materiality: 0.80
Item codes: 1.01, 2.02, 3.02, 7.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Korro Bio raises $85M in PIPE led by Venrock; cash runway into H2 2028
----------------------------------------------------------------------

- Gross proceeds ~$85M from 4,501,928 shares at $11.11 and 3,148,836 pre-funded warrants at $11.109.
- Preliminary cash, equivalents, marketable securities of $85.2M as of Dec 31, 2025; runway through H2 2028.
- Proceeds fund clinical milestones: KRRO-121 for urea cycle disorders and GalNAc-conjugated AATD program.
- Closing expected March 10, 2026; placement agents include Citigroup, Cantor, Oppenheimer, William Blair.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1703647/000119312526097575/0001193125-26-097575-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1703647/000119312526097575/krro-20260309.htm
  HTML page:      https://secwatch.observer/filing/0001193125-26-097575

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer